Since extent of myocardial cell death is the primary determinant of outcome from 63 planned or unplanned cardiac ischemia, protective strategies to limit this damage 64 during ischemia-reperfusion (I/R) are highly sought after. It is now clear that a 65 number of GPCR families can activate cytoprotective responses. These receptors, 66 including the adenosine, opioid and bradykinin families, may act not only as acute 67 
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Adenosine Receptors and Reperfusion Injury of the Heart "retaliatory" systems mediating immediate responses to injurious stimuli, but func-68 tion as sensors of low-level stress to initiate a signaling cascade culminating in the 69 expression of more prolonged protected phenotypes. These adaptive or hormesis 70 responses predate mammals, and offer potential as targets for therapeutic cardio-71 protection.
72
The AR family, composed of A 1 , A 2A , A 2B , and A 3 subtypes, has been impli-73 cated in both acute protection and adaptive preconditioning (PC) responses. Not 74 only does preischemic activation of ARs generate potent protection, but significant 75 evidence indicates that this receptor class also mediates powerful cardioprotection 76 when targeted during the reperfusion phase. This brief review focuses on tempo-77 ral properties of AR-mediated cardioprotection (prior to, during, after ischemia), 78 their contributions to PC responses, and their relevance to the protection of human 79 myocardium. Given early evidence of cardioprotection in response to adenosine and (subse-83 quently) selective A 1 AR agonism, the A 1 AR subtype seemed an obvious target 84 for manipulating myocardial ischemic tolerance. To test the hypothesis that A 1 AR 85 density (rather than endogenous [ligand] ) limits the resistance of the heart to I/R, 86 Matherne and colleagues developed a cardiac-specific A 1 AR overexpression model. 87 The model employed a construct containing the rat A 1 AR gene under the control of 88 a mutated α-myosin heavy chain promoter (Matherne et al. 1997) , with extent of 89 A 1 AR expression varying across the lines generated (with up to 100-fold overex-90 pression of coupled A 1 ARs). The resulting phenotype was characterized by modest 91 bradycardia, conduction disturbances, and a small increase in heart mass in some 92 lines (Matherne et al. 1997; Gauthier et al. 1998; Kirchhof et al. 2003) . Initial studies 93 of I/R revealed profound reductions in cell death and contractile dysfunction com-94 pared with wild-type hearts (Matherne et al. 1997; Headrick et al. 1998; Morrison 95 et al. 2000) . Tolerance to hypoxic challenge , and long-term 96 cold storage of hearts (Crawford et al. 2005) were also improved. Cardioprotection 97 was evident in isolated tissue preparations (Matherne et al. 1997; Headrick et al. 98 1998) and in vivo (Yang et al. 2002) . These outcomes were consistent with pro-99 tective effects of artificially enhanced A 1 (and A 3 ) expression in isolated myocytes 100 (Dougherty et al. 1998 ). Differing components of cardiac protection were apparent, 101 with reduced necrosis and infarction (Matherne et al. 1997; Morrison et al. 2000; 102 Yang et al. 2002) , inhibition of apoptosis (Regan et al. 2003; Crawford et al. 2005) , 103 enhancement of bioenergetic state during ischemia (Headrick et al. 1998) , and se-104 lective modulation of contractile injury: A 1 AR overexpression consistently reduces 105 diastolic (and not systolic) dysfunction during I/R (Matherne et al. 1997; Reichelt 106 et al. 2007 ). The latter suggests that A 1 ARs selectively target processes underlying 107 diastolic contracture (e.g., Ca 2+ handling, myofibrillar function).
While the signaling basis of cardioprotection with A 1 AR overexpression re-109 mains to be established, analysis to date implicates players common to protec-110 tive signaling in wild-type tissue, including mitochondrial ATP-sensitive K + (mito 111 K ATP ) channels and inducible nitric oxide synthase (iNOS) 112 Nayeem et al. 2003) . Curiously, mito K ATP channels (or 5-hydroxydecanoate-113 sensitive targets) were not implicated in protection against hypoxia (Cerniway 114 et al. 2002) . Other work supports a role for p38 mitogen-activated protein kinase 115 (p38-MAPK)-dependent signaling, though this remains to be more fully tested 116 (Jones et al. 1999) . Sarcoplasmic reticulum (SR) Ca 2+ handling is impaired (Zucchi 117 et al. 2002) , which could contribute to specific aspects of associated cardiopro-118 tection. Another interesting outcome with A 1 AR overexpression is restoration of 119 ischemic resistance in aged hearts: aging may limit the capacity of hearts to with-120 stand damage during I/R (Willems et al. 2005) , and this effect was reversed by 121 A 1 AR overexpression in mice (Headrick et al. 2003b) , in parallel with restoration 122 of adenosine responsiveness.
123
In terms of PC responses, overexpression of A 1 ARs mimics the benefit with 124 this stimulus, actually surpassing the degree of protection with ischemic PC (IPC) 125 (Morrison et al. 2000) . Protection with A 1 AR overexpression is also nonadditive 126 with IPC, suggesting a commonality of signaling/end-effectors and/or maximally 127 effective protection with A 1 AR overexpression. However, the latter is inconsistent 128 with reports that acute application of adenosine (Peart et al. 2002) or A 1 AR agonist 129 (Nayeem et al. 2003) can augment the protection with A 1 AR overexpression.
130
Overexpression of A 1 ARs in cardiac cells did confirm the hypothesis that nor-131 mal levels of A 1 AR expression in wild-type hearts do appear to limit the extent of 132 cardioprotection possible, and thus the heart's intrinsic resistance to I/R (Matherne 133 et al. 1997 ). Nonetheless, pharmacologically activating A 1 ARs does provide benefit 134 in wild-type hearts (see Sect. 2.1.1 below), demonstrating that normally expressed 135 A 1 ARs can be targeted to achieve further cardioprotection. This may reflect addi-136 tional effects of transient AR agonism (and induction of a short-lived PC state), as 137 opposed to the longer-lived effects of tonic A 1 AR activity in transgenic hearts. Since its discovery by Murry and colleagues (Murry et al. 1986 ), the molecular 141 basis of IPC has been the subject of intense investigation. An ultimate goal is trans-142 lation to the clinical setting, enabling activation of similar protection in cardiac 143 patients. Through a simplified scheme, we can examine the roles of ARs in PC 144 responses from the viewpoint of the initial "trigger" phase and the subsequent "me-145 diation" phase.
146
The initial and rather crude ischemic trigger of PC is now known to involve 147 the release and actions of several GPCR ligands (including opioids, bradykinin, and 148 adenosine). A "threshold" model for triggering PC has evolved, in which summation 149 U n c o r r e c t e d P r o o f BookID 158970 ChapID 7 Proof# 1 -02/04/09
Adenosine Receptors and Reperfusion Injury of the Heart of multiple GPCR stimuli is required to activate delayed protection (Goto et al. 150 1995; Baba et al. 2005) . The response may involve not only summation of GPCR 151 triggers but also downstream kinase signaling (Vahlhaus et al. 1998) . The kinase 152 cascades involved in PC have been elaborated over recent years, and are currently 153 thought to converge on modulation of mitochondrial effectors, including K ATP chan-154 nels and the mitochondrial permeability transition pore (MPTP) (Murphy 2004; 155 Hausenloy and Yellon 2007; Liem et al. 2008) . Nonetheless, there remains con-156 siderable disagreement regarding the roles of different signaling components, and 157 putative end-effectors, in AR-mediated protection and PC. As the focus of this re-158 view is on AR involvement in cardioprotection, and since the signaling basis of PC 159 responses has been very well addressed in recent reviews (Murphy 2004; Downey 160 et al. 2007; Hausenloy and Yellon 2007) , interested readers are directed to these for 161 further details. 
Adenosine as a Preischemic Trigger of PC

163
It should be clarified that true PC describes a delayed protective state persisting in 164 the absence of the initial stimulus. Many studies refer to "preconditioning" effects 165 when assessing preischemic receptor or pathway activation. However, application 166 of receptor agonists up to induction of ischemia (with no intervening washout) will 167 modify the same targets during ischemia and possibly early reperfusion. This is an 168 inherent limitation to in vivo studies, since exogenously applied AR agonists (or 169 antagonists) may be slowly removed and thus exert potentially long-lasting effects 170 beyond the desired "window." Thus, while discussion of the effects of preischemic 171 AR activation (or antagonism) can be informative in terms of roles of ARs in PC 172 responses, these experimental scenarios do not simulate PC per se.
173
In seeking a released factor capable of transducing protection with PC, adeno-174 sine seemed a likely candidate: adenosine release increases rapidly in response 175 to different conditions of stress (Headrick et al. 2003a) ; the interstitial concen-176 trations achieved are sufficient to activate one or more AR subtypes (Van Wylen 177 1994; Lasley et al. 1995a; Headrick 1996; Harrison et al. 1998) ; rapid transport and 178 catabolism ensures a brief extracellular half-life and localized signaling; and exoge-179 nous AR agonists appear to induce similar protective states. In early work Liu et al. showed that preischemic treatment with adenosine or N 6 -182 1-(phenyl-2R-isopropyl) adenosine (PIA) mimicked the protective effects of PC in 183 rabbit myocardium (Liu et al. 1991) . Subsequent studies confirmed protection via 184 preischemic A 1 AR agonism in different models and species (Lasley and Mentzer 185 1992; Thornton et al. 1992; Liu and Downey 1992; Tsuchida et al. 1993; Strickler 186 et al. 1996; Carr et al. 1997; Liang and Jacobson 1998; de Jonge and de Jong 187 U n c o r r e c t e d P r o o f BookID 158970 ChapID 7 Proof# 1 -02/04/09 J.P. Headrick and R.D. Lasley 1999; de Jonge et al. 2002; Germack et al. 2004; Germack and Dickenson 188 2005) . Toombs and colleagues not only showed that preischemic adenosine 189 limited infarct size (Toombs et al. 1992) , but further showed that activation of 190 8-ρ-sulfophenyltheophylline-sensitive ARs (likely A 1 and/or A 2 ARs) during the 191 ischemic period itself was required for protection.
192
Preischemic activation of the A 3 AR subtype can also generate cardiac protection. 193 Strickler et al. (1996) presented some of the first evidence that A 3 AR activation prior 194 to ischemia could confer protection against ischemia-like insult in myocytes (of 195 avian origin), while Tracey and colleagues acquired evidence for A 3 AR-triggered 196 protection in rabbit hearts . Other groups confirmed A 3 AR-197 mediated protection in multiple models (Strickler et al. 1996; Carr et al. 1997; Liang 198 and Jacobson 1998; de Jonge et al. 2002; Maddock et al. 2002; Germack et al. 2004; 199 Germack and Dickenson 2005; Wan et al. 2008) . Indeed, Liang and Jacobson (1998) 200 found that the A 3 AR induced a more sustained state of protection than the A 1 AR 201 when activated prior to ischemia.
202
In contrast to PC-like effects of A 1 AR or A 3 AR agonism, preischemic activa-203 tion of A 2A ARs or A 2B ARs is generally ineffective in limiting myocardial injury 204 during subsequent I/R (Thornton et al. 1992; Lasley and Mentzer 1992; Maddock 205 et al. 2002; Germack and Dickenson 2005) . Studies with the natural agonist adeno-206 sine yield mixed results, likely due to rapid uptake and catabolism of extracellular 207 adenosine, complications of potent hemodynamic actions of the endogenous ago-208 nist, and the impact of mixed AR activation on different cell types. 
ARs as Intrinsic Triggers of IPC
210
Studies demonstrating PC-like responses to preischemic AR activation provided 211 support for AR involvement in IPC. To more directly test for a role of AR acti-212 vation in triggering nonpharmacological forms of PC, AR antagonists or adenosine 213 deaminase have been added, often in both trigger and mediation phases, to limit 214 any contributions from ARs. A number of these studies independently provided no 215 evidence for essential roles for ARs in PC Lasley et al. 216 1993; Hendrikx et al. 1993; Bugge and Ytrehus 1995; Lasley et al. 1995b), lead-217 ing to premature elimination of this class of GPCRs as contributing to PC (Cave 218 et al. 1993; Li and Kloner 1993) . In the context of protective thresholds and con-219 tributions of multiple stimuli, a more accurate conclusion may be that the roles of 220 ARs in triggering/mediating PC are redundant, with other concomitant stimuli (e.g., 221 endogenous opioids and bradykinin) being able to compensate and surpass the sig-222 naling threshold required for protection.
223
On the other hand, considerable evidence supporting essential AR involvement 224 in PC has been reported. Studies employing different AR antagonists or adeno-225 sine deaminase supported roles in rabbit (Liu et al. 1991; Tsuchida et al. 1992; 226 Thornton et al. 1993; Urabe et al. 1993; Weinbrenner et al. 1997 ) rat (Headrick 227 1996; de Jonge and de Jong 1999; de Jonge et al. 2001; Tani et al. 1998) , dog 228 (Auchampach and Gross 1993; Hoshida et al. 1994) , and pig (Schulz et al. 1995; 229 U n c o r r e c t e d P r o o f BookID 158970 ChapID 7 Proof# 1 -02/04/09
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232
Reasons for differing outcomes with AR blockade in varied models of PC are not 233 clear. Evidence has been presented for substantial species differences in adenosine 234 handling and receptor activation (Headrick 1996) , which might dictate differing 235 roles for adenosine and certainly contribute to differing abilities of competitive AR 236 antagonists to limit these responses. Moreover, the affinity and selectivity of AR 237 ligands varies across species, and in the event of poor solubility, bioavailability may 238 limit the effects of a ligand. Furthermore, the relative contributions of adenosine and 239 ARs in triggering PC may be species dependent, with a greater and essential contri-240 bution in rodent myocardium. Nonetheless, evidence for essential AR involvement 241 has been reported in large animal models (Auchampach and Gross 1993; Hoshida 242 et al. 1994; Schulz et al. 1995; Vogt et al. 1996; Louttit et al. 1999 ) and in human 243 tissue (Walker et al. 1995; Tomai et al. 1996; Ikonomidis et al. 1997) . Responses 244 may be model specific, in part, since some aspects of I/R injury are dependent upon 245 blood components and activation of pathways for inflammation, while others are in-246 trinsic to the myocardial cells themselves (and these cell-dependent responses may 247 also vary across species). Thus, injury and counteracting protective processes may 248 differ between ex vivo or blood-free models and the in situ myocardium. Finally, 249 differences reported with the use of AR antagonists in PC studies may be related 250 to the nature and duration of the PC stimulus (see below), which may influence the 251 contribution of ARs to protection.
252
In terms of the identity of the ARs implicated in triggering PC, initial work 253 supported the involvement of A 1 ARs (Liu et al. 1991; Tsuchida et al. 1992; Aucham-254 pach and Gross 1993). However, subsequent studies Ganote 1994, 255 1995; Liu et al. 1994; Wang et al. 1997) demonstrated that partially selective A 3 AR 256 antagonism also impaired the protective efficacy of PC. Liang and colleagues doc-257 umented A 1 AR and A 3 AR involvement in PC responses in chick cardiomyocytes 258 (Strickler et al. 1996; Liang and Jacobson 1998) , while Wang et al. (1997) reported 259 additive contributions from A 1 AR and A 3 ARs to optimize PC in rabbit myocytes. 260 Although other studies initially supported A 3 AR involvement in IPC in intact rab-261 bit myocardium , this group subsequently presented evidence of 262 a quantitatively more critical role for A 1 AR vs. A 3 AR (Hill et al. 1998 ). More re-263 cent studies confirm that endogenous adenosine contributes to IPC via A 1 AR and/or 264 A 3 AR activation, though the contribution of ARs may be dependent upon the nature 265 and duration of the PC stimulus, being less important with shorter periods of trigger-266 ing ischemia (Liem et al. 2001 (Liem et al. , 2008 . This is consistent with earlier observations 267 of Schulz et al. in pigs (1995) . 268 Ultimately, preservation of AR-dependent protection in human myocardial tis-269 sue is of key importance. Walker and colleagues provided some of the first support 270 for mediation of PC by ARs in human myocardium (Walker et al. 1995 ). Cleveland 271 et al. (1996 , 1997 subsequently confirmed AR-mediated PC responses in human 272 myocardial tissue. Carr et al. (1997) dependence of PC in human pediatric myocytes. Thus, AR-mediation of PC is rele-275 vant to human myocardium. Indeed, an early study by Tomai et al. (1996) supported 276 A 1 AR-dependent PC in patients undergoing coronary angioplasty. Furthermore, the 277 importance of ARs in determining resistance to myocardial ischemia is supported 278 by associations between AR polymorphisms, specifically for A 1 and A 3 ARs, and 279 infarct size in patients with ischemic cardiomyopathy (Tang et al. 2007 (Guo et al. 2001) , apparently negating an essential role for this AR 284 subtype. However, A 1 AR KO eliminates protection with both IPC (Lankford et al. 285 2006) and remote PC triggered by cerebral ischemia (Schulte et al. 2004 ). More-286 over, ecto-5 -nucleotidase deletion also eliminates protection with IPC, supporting 287 an essential role for endogenous adenosine generated at the cell surface (Eckle et al. 288 2007) . This latter study also confirmed an essential role for ARs in IPC, although 289 their data differed in implicating only the A 2B AR. The basis of this discrepancy is 290 not clear, but may, in part, be model related (in vivo vs. in vitro). This latter obser-291 vation is, however, consistent with recent data from the laboratory of Downey and 292 colleagues, who reported evidence for protein kinase C (PKC) dependent sensitiza-293 tion of A 2B ARs during the trigger or ischemic phases and their role in protection 294 during the subsequent reperfusion phase (Kuno et al. 2007 ).
295
Of course, a limitation inherent to gene deletion (or overexpression) is an inabil-296 ity to distinguish events temporally. Since gene deletion eliminates the actions of 297 targeted ARs at all time points, it is unclear from such work when the receptors are 298 involved. For example, A 1 ARs or A 3 ARs may trigger protection with IPC prior to 299 or during ischemia, while recent evidence implicates a role for A 2B AR in mediat-300 ing the protection with PC during the reperfusion phase (Kuno et al. 2007 ). This 301 A 2B AR-mediated protection during reperfusion could depend to some extent upon 302 A 1 AR and/or A 3 AR activation of PKC prior to or during ischemia. Such complex 303 responses are not amenable to interrogation by gene manipulation. 
AR Activity During Ischemia
305
Cardioprotective effects of PC and preischemic GPCR activation were initially 306 thought to manifest primarily during ischemia itself . Preis-307 chemic AR agonism (or A 1 AR overexpression) modifies substrate and energy 308 metabolism, H + and Ca 2+ accumulation, and contracture development during the 309 ischemic episode (Lasley et al. 1990; Fralix et al. 1993; 310 Headrick 1996) . Similarly, there is evidence of specific protective actions of adeno-311 sine and A 1 ARs during ischemia versus reperfusion 312 U n c o r r e c t e d P r o o f BookID 158970 ChapID 7 Proof# 1 -02/04/09
Adenosine Receptors and Reperfusion Injury of the Heart Peart et al. 2003) . IPC also modifies ischemic events relevant to tissue protec-313 tion (de Jonge et al. 1999) , reducing purine moiety accumulation and washout (Van AQ1 314 Wylen 1994; Lasley et al. 1995a; Harrison et al. 1998; de Jonge et al. 2002) and ionic 315 perturbations (Fralix et al. 1993) . Such observations are consistent with the idea that 316 modulation of injury during ischemia itself contributes to overall protection and im-317 proved postischemic outcome. This is supported by early work of Thornton et al. 318 (1993) , who showed that protection with IPC is mediated, at least in part, via intrin-319 sic activation of A 1 ARs during the subsequent ischemic insult. Studies such as that 320 of Stambaugh et al. (1997) also show that AR activation throughout the period of 321 ischemia/hypoxia is beneficial.
322
While a majority of studies across differing species support beneficial actions 323 of either exogenously or intrinsically activated ARs during myocardial ischemia, 324 there are a small number of reports of improved outcomes with AR antagonists 325 applied prior to ischemia in vivo (and thus reflecting possible blockade of ARs 326 prior to, during, or following ischemia). Neely et al. (1996) initially documented 327 infarct limitation with three different A 1 AR antagonists, DPCPX (1,3 dipropyl-328 8-cyclopentylxanthine), XAC (xanthine amine congener) and bamiphylline, in a 329 feline regional myocardial infarct model. To rule out that the possibility that these 330 A 1 AR antagonists were producing their effects via a nonspecific intracellular ac-331 tion (i.e., inhibition of intracellular enzymes, e.g., phosphodiesterases), Forman and 332 colleagues (2000) reported that another (albeit poorly selective) A 1 AR antagonist, 333 DPSPX (1,3-dipropyl-8-p-sulfophenylxanthine), which is negatively charged and 334 thus does not accumulate in intracellular spaces because of its high water solubil-335 ity, also reduced infarct size in dogs. Because DPSPX significantly reduced FMLP 336 (formyl-Met-Leu-Phe)-induced chemoattraction of human neutrophils, the authors 337 of this study suggested that this A 1 AR antagonist produced sustained myocardial 338 protection in dogs by reducing inflammation. However, DPSPX is also known to 339 interact with the A 2B AR (Feoktistov and Biaggioni 1997) , and at the doses applied 340 in this study, to block A 2 -dependent coronary dilation (Forman et al. 2000) . A later 341 detailed study by Auchampach et al. (2004) whereas the same receptor limits injury in cardiomyocytes. A number of studies 358 confirm a lack of any infarct-sparing effects of nonselective or subtype-specific AR 359 antagonists in vivo in multiple species (Toombs et al. 1992; Tsuchida et al. 1992 ; 360 Auchampach and Gross 1993; Thornton et al. 1993; Zhao et al. 1993; Hoshida et al. 361 1994; Baba et al. 2005; Kin et al. 2005; Lasley et al. 2007 ). However, with the 362 exception of the study by Zhao et al. (1993) , the antagonists used in these studies 363 were administered as single doses and not as continuous infusions or multiple doses 364 to achieve a steady state plasma concentration of the AR antagonist, as was done 365 by Neely et al., Forman et al., and Auchampach et al. . Moreover, problems with the 366 selectivity of AR antagonists for specific AR subtypes, particularly during in vivo 367 studies, limit their interpretation with respect to the definitive roles of the four AR 368 subtypes in the setting of acute myocardial ischemia-reperfusion injury. 
Reperfusion Injury and ARs in Experimental Studies
370
Although reperfusion is necessary to salvage ischemic myocardium, the process 371 of restoring blood flow also contributes to the total injury observed in ischemic-372 reperfused myocardium. Reperfusion injury is caused by intracellular calcium over-373 load and oxidative stress induced by the formation of reactive O 2 species (ROS) in 374 the presence of decreased cellular redox state. Reperfusion injury in intact animals 375 and in humans following myocardial ischemia durations of >15 min produces irre-376 versible injury that is also associated with a general inflammatory process including 377 the release of numerous cytokines, adhesion and infiltration of neutrophils across 378 the damaged coronary endothelium, platelet aggregation, and activation of the com-379 plement cascade (Ambrosio and Tritto 1999; Park and Lucchesi 1999; Verma et al. 380 2002).
381
Similar to the beneficial protective effects of AR agonists discussed in the first 382 sections of this chapter, there is now convincing evidence that the activation of ARs 383 during reperfusion is cardioprotective in animal models. However, in contrast to 384 reports nearly 20 years old documenting the cardioprotective effects of adenosine 385 treatment prior to ischemia, initial studies on the effects of treatment with adenosine 386 after reperfusion were much more controversial. Two initial reports in canine models 387 indicated that intracoronary and intravenous adenosine infusions for the first 1-2.5 h 388 of reperfusion after 90 min coronary occlusions significantly reduced infarct size 389 after 24 and 72 h reperfusion, respectively (Olafsson et al. 1987; Pitarys et al. 1991) . 390 In both of these studies, the ischemic myocardium from animals treated with adeno-391 sine exhibited significantly less neutrophil accumulation and erythrocyte plugging 392 of capillaries. These observations are consistent with adenosine's ability to inhibit 393 both neutrophil adherence to endothelium (Cronstein et al. 1992 ) and platelet aggre-394 gation (Söderbäck et al. 1991) . Several subsequent reports were, however, unable to 395 reproduce these positive findings (Homeister et al. 1990; Goto et al. 1991; Vander 396 Heide and Reimer 1996). Negative results with adenosine treatment following reper-397 fusion may be due to the use of inadequate doses, which must be high enough to 398 overcome its rapid uptake and metabolism by red blood cells and endothelial cells. 399 
U n c o r r e c t e d P r o o f
Adenosine Receptors and Reperfusion Injury of the Heart
However, high concentrations of adenosine can be associated with severe hypoten-400 sion, reflex tachycardia, and coronary steal. These side effects will likely limit the 401 use of adenosine as a cardioprotective agent in humans. Although there is a significant expression of A 2A ARs on vascular cells (vascular 419 smooth muscle and endothelial cells), and activation of this receptor is associated 420 with coronary vasodilatation, the beneficial effects of reperfusion A 2A AR agonists 421 are independent of increased coronary blood flow and can be achieved without 422 systemic hypotension. The prevailing current hypothesis for the beneficial A 2A AR 423 effects during reperfusion are related to its anti-inflammatory properties, such as 424 inhibition of neutrophil production of ROS and adherence to endothelium (Visser 425 et al. 2000; Sullivan et al. 2001) . Recent studies in mice further suggest that this 426 A 2A AR-mediated reperfusion protection is due to effects on bone marrow-derived 427 cells, more specifically to CD4 + T-helper lymphocytes . 428 However, two additional studies conducted in intact animal models of myocar-429 dial stunning indicate that reperfusion treatment with A 2A AR agonists can exert 430 beneficial effects in the absence of severe inflammation and myocardial necrosis. In 431 porcine regionally stunned myocardium, an intracoronary infusion of the A 2A AR 432 agonist CGS21680, initiated after 2 h reperfusion following 15 min coronary oc-433 clusion, significantly increased regional preload-recruitable stroke work and stroke 434 work area, both of which are load-insensitive parameters of cardiac contractility. 435 This effect, which appeared to be independent of increased coronary blood flow, 436 occurred in stunned (i.e., no infarction was detected), but not normal, myocardium 437 (Lasley et al. 2001) . The fact that the A 2A AR agonist exerted its beneficial effects 438 2 h after reperfusion suggests that the improvement in regional contractility is likely 439 to have been independent of a reduction in myocardial reperfusion injury, but rather 440 Glover et al. (2007) observed that the A 2A AR agonist ATL-146e, 442 given just prior and during reperfusion following multiple brief (5 min) coronary 443 occlusions, improved reperfusion wall thickening in the absence of any increase 444 in coronary blood flow. Infusion of ATL-146e had no effect on regional function 445 in normally perfused myocardium. Whether these beneficial effects of reperfusion 446 A 2A AR stimulation in the absence of necrosis are due to a direct effect on the my-447 ocardium remains to be determined. 448 Although the evidence implicating the anti-inflammatory effects of postischemic 449 A 2A AR activation in the setting of myocardial infarction is compelling, the above 450 two studies in stunned myocardium indicate that A 2A AR activation may also protect 451 the reperfused heart via mechanisms independent of neutrophils and inflammatory 452 processes, as well as increased coronary blood flow. There are several reports that 453 A 2A ARs are expressed in porcine, human, and rat ventricular myocytes (Marala and 454 Mustafa 1998; Kilpatrick et al. 2002) , which raises the possibility that the beneficial 455 effect of A 2A AR agonists during reperfusion may also be due to direct effects on 456 the cardiac myocyte. There have been numerous studies over the past 15 years in-457 vestigating the effects of A 2A AR agonists on cardiac myocyte physiology, but these 458 reports have yielded conflicting findings (Shryock et al. 1993; Stein et al. 1994; 459 Xu et al. 1996 459 Xu et al. , 2005 Boknik et al. 1997; Woodiwiss et al. 1999 (Kin et al. 2005; Reid et al. 2005; 470 Lasley et al. 2007) . However, there is evidence that the A 2A AR does participate in 471 the cardioprotective effect of ischemic postconditioning. Ischemic postconditioning 472 is the phenomenon by which brief interruptions in coronary flow during the initial 473 minutes of reperfusion following a prolonged occlusion reduce myocardial infarct 474 size. This phenomenon is thus somewhat analogous to ischemic preconditioning, 475 which was described earlier. The AR antagonist ZM241385 (4-(2-[7-amino-2-(2-476 furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol), which exhibits 477 some selectivity for the A 2A AR subtype, has been shown to block ischemic post-478 conditioning in vivo in rat hearts and in isolated perfused mouse hearts (Kin et al. 479 2005) . A more recent report indicated that ischemic postconditioning could not be 480 induced in mouse hearts from A 2A AR KO mice (Morrison et al. 2007 ). These find-481 ings indicate that stimulation of A 2A ARs plays a pivotal role in reducing myocardial 482 reperfusion injury. Observations in isolated buffer perfused hearts in these latter two 483 reports further support the hypothesis that this protective effect is mediated, at least 484 in part, by the cardiomyocyte A 2A AR. Adenosine Receptors and Reperfusion Injury of the Heart As described above, there are now numerous reports indicating that the in-486 fusion of A 2A AR agonists during reperfusion is cardioprotective. Although the 487 administration of A 2A AR agonists prior to ischemia does not reduce myocar-488 dial ischemia-reperfusion injury, there is increasing evidence that A 2A ARs may 489 modulate the protective effects of A 1 AR stimulation. Reid et al. (2005) and 490 Lasley et al. (2007) reported that the A 2A AR antagonist ZM241385 blocked 491 the infarct reducing effects of preischemic treatments with three different 492 AR agonists-AMP579 (1S-[1a, 2b, 3b, 4a 494 2 chloro-N 6 -cyclopentyladenosine (CCPA), 5 -N-ethyl-carboxamidoadenosine 495 (NECA)-in two different studies. The A 2A AR antagonist did not alter the A 1 AR-496 induced bradycardia with these agonists, indicating that the A 1 AR was not blocked; 497 however, the ability of ZM241385 to block the protection by these AR agonists 498 was comparable to that achieved with the A 1 AR antagonist DPCPX. Preliminary 499 observations in one of these studies suggested that the A 2A AR antagonist par-500 tially blunted the effects of AMP579 on preischemic mitogen-activated protein 501 kinase (MAPK) signaling (Reid et al. 2005) . These findings regarding the effects 502 of A 2A AR antagonists on A 1 AR cardioprotection are supported by an increasing 503 number of reports of interactions between AR subtypes, including the formation 504 of heterodimers (Karcz-Kubicha et al. 2003; O'Kane and Stone 1998; Lopes et al. 505 1999 Lopes et al. 505 , 2002 Nakata et al. 2005 ).
506
There is also evidence that the beneficial effects of reperfusion AR agonist treat-507 ments may involve interactions among AR subtypes. In the isolated perfused rabbit 508 heart, a reperfusion infusion (500 nM) of the AR agonist AMP579, which has a high 509 affinity for both A 1 and A 2A ARs ), reduced infarct size-an ef-510 fect that was blocked by 8-(13-chlorostyryl) caffeine (CSC), which exhibits some 511 selectivity for A 2A ARs, but not by the A 1 AR antagonist DPCPX (Xu et al. 2001) . 512 The beneficial effect of AMP579 was mimicked by the nonselective agonist NECA 513 at a dose (100 nM) activating both A 1 and A 2A ARs, but not by the A 2A AR agonist 514 CGS21680 (50 nM). Kis et al. (2003) reported similar findings in the intact rabbit, 515 where an infusion of AMP579 during reperfusion reduced infarct size, and this ef-516 fect was blocked by the A 2A AR antagonist ZM241385 but not mimicked by the 517 same dose of the A 2A AR agonist CGS21680. It is not clear why these studies did 518 not observe protection with the A 2A AR agonist alone, when numerous other studies 519 have reported such protection; however, these findings support a role for the A 2A AR 520 in reduction of myocardial injury. Since ZM241385 has some affinity for A 2B ARs, 521 it is also possible that the effects of this agent could be due to antagonism of this 522 receptor subtype (Hasan et al. 2000) . which appear to be expressed in the heart, it is possible that one or more of these 527 other AR subtypes may modulate reperfusion injury. The one exception to this 528 hypothesis is the A 1 AR. Although, as described in the first section of this chapter, 529 there is significant evidence that A 1 AR agonists administered prior to ischemia are 530 protective, it is clear that A 1 AR agonists administered during reperfusion are not 531 protective (Thornton et al. 1992; Baxter et al. 2000) . There is evidence that A 3 AR 532 activation during reperfusion may be cardioprotective, as studies in isolated hearts 533 and intact animals indicate that the A 3 AR agonists IBMECA (1-deoxy-1-[6-[[ 534 (3-iodophenyl) methyl]amino]-9H -purin-9-yl]-N-methyl-b-D-ribofuranuronamide) 535 and methyl]amino]-9H -purin-9-yl]-536 1-deoxy-N-methyl-b-D-ribofuranuronamide), administered during reperfusion, 537 reduce myocardial infarct size (Maddock et al. 2002; Auchampach et al. 2003; 538 Park et al. 2006 ). In two of these studies, the effects of the A 3 AR agonists were 539 blocked by A 3 AR antagonists (Maddock et al. 2002; Park et al. 2006). Interestingly, 540 in the former study (Maddock et al. 2002 ) the reperfusion A 3 AR agonist protection 541 was also blocked by the A 2A AR antagonist CSC. Finally, Kin et al. (2005) observed 542 that postconditioning could be blocked by an A 3 AR antagonist. Thus, in contrast 543 to the A 1 AR, activation of the A 3 AR either prior to ischemia or during reperfusion 544 appears to be cardioprotective. 
Emerging Roles for the A 2B AR During Reperfusion
546
With respect to the fourth AR subtype, only now are a limited number of studies 547 supporting a role for the A 2B AR in modulating myocardial reperfusion injury ap-548 pearing. Investigations of this receptor in the heart have been hindered by the fact 549 that there are no radioligand binding studies defining A 2B AR receptor density or 550 affinity in mammalian myocardium or cardiomyocytes. The role of this receptor has 551 also been hindered by the lack of studies with well-characterized, selective A 2B AR 552 agonists and antagonists. To date there are four pharmacological studies providing 553 some evidence for the involvement of A 2B ARs, although the results are conflicting. 554 Auchampach et al. (2004) reported that reperfusion treatments with DPCPX and 555 BG 9928, but not BG 9719, all of which are selective A 1 AR antagonists, reduced 556 infarct size in dogs by ∼40%. These effects were compared to radioligand binding 557 studies performed with recombinant canine ARs expressed in HEK cells, and block-558 ade of canine A 1 (heart rate) and A 2A AR (coronary conductance) effects. Based on 559 these observations, the authors concluded that DPCPX and BG 9928 may exert their 560 infarct-reducing effects by blocking A 2B ARs; however, they could not discount the 561 possibility that DPCPX and BG 9928 reduced infarct size by blocking A 1 ARs.
562
Three additional studies in rabbit heart models of ischemia/reperfusion con-563 cluded that A 2B AR activation, rather than inhibition, contributes to reperfusion 564 cardioprotection (Solenkova et al. 2006; Phillip et al. 2006; Kuno et al. 2007 ). In the 565 first of these studies, the infarct-reducing effect of IPC was blocked by the A 2B AR 566 antagonist, MRS1754 (N-(4-cyanophenyl)-2- [4-(2,3,6,7-tetrahydro-2,6-dioxo-1, 567 U n c o r r e c t e d P r o o f BookID 158970 ChapID 7 Proof# 1 -02/04/09
Adenosine Receptors and Reperfusion Injury of the Heart 3-dipropyl-1H -purin-8-yl)phenoxy]-acetamide), but not an A 2A AR antagonist, 568 CSC, administered at the onset of reperfusion. Subsequently, Phillip et al. (2006) 569 reported that the cardioprotective effect of NECA administration at reperfusion (i.e., 570 pharmacological postconditioning) in intact rabbits was blocked by MRS1754. 571 Interestingly, a previous report from this same laboratory concluded that the 572 reperfusion protection induced by NECA was due to A 2A AR activation (Xu et al. 573 2001). More recently, Kuno et al. (2007) demonstrated that a novel A 2B AR agonist, 574 BAY 60-6583, administered during reperfusion, is protective. Given the apparent 575 expression of multiple AR subtypes in the heart and their possible interactions, as 576 well as the lack of selectivity for many of the commonly used AR agonists and 577 antagonists, studies in AR KO mice will likely be needed to address the question 578 of the A 2B AR, as well as the definitive roles of other AR subtypes. Interestingly, 579 the results of a recent study by Eckle et al. (2007) Despite all of the experimental evidence to date indicating the cardioprotective ef-583 fects of adenosine and AR agonists, there have been very few studies examining the 584 beneficial effects of these agents in humans in the setting of myocardial ischemia-585 reperfusion and thrombolysis. The initial such report was the acute myocardial 586 infarction study of adenosine (AMISTAD) trial conducted between December 1994 587 and July 1997, the results of which were published in 1999 (Mahaffey et al. 1999) . 588 This was an open-label, placebo-controlled, randomized study to determine the 589 safety and efficacy of adenosine as an adjunct to thrombolytic therapy in the treat-590 ment of acute myocardial infarction (MI). The effect of an intravenous infusion 591 of adenosine (70 μg kg −1 min −1 ) for 3 h was compared to a placebo infusion in 592 patients treated with thrombolysis within 6 h of the onset of an MI. After modifi-593 cation for slow enrollment, 197 patients were included, with the primary end-point 594 being myocardial infarct size, as determined by Tc-99m sestamibi single-photon 595 emission computed tomography (SPECT) imaging 5-7 days after enrollment. The 596 results indicated that there was a 33% relative reduction in infarct size in patients 597 that received adenosine (p = 0.03). Patients with an anterior MI exhibited a 67% 598 relative reduction in infarct size, whereas there was no beneficial effect in patients 599 with a nonanterior MI. Patients receiving adenosine, particularly those with nonan-600 terior MI, experienced more bradycardia, heart block, hypotension and ventricular 601 arrhythmias (Mahaffey et al. 1999). 602 There is a significant amount of preclinical data on the efficacy of AR agonists 603 in reducing myocardial reperfusion injury, and these studies are clearly more con-604 sistently positive than the often contradictory findings with adenosine. Despite this 605 wealth of information, today there remains only one documented clinical trial ex-606 amining the effects of an AR agonist in the setting of clinical myocardial ischemia-607 reperfusion injury, the ADMIRE (AMP579 Delivery for Myocardial Infarction 608 REduction) study. This was a double-blind, multicenter, placebo-controlled trial of 609 311 patients undergoing primary percutaneous transluminal coronary angioplasty 610 (PTCA) after acute ST-segment elevation MI (Kopecky et al. 2003) . Patients were 611 randomly assigned to placebo or to one of three different doses of AMP579 (15, 612 30 or 60 μg kg −1 ) continuously infused over 6 h. This AR agonist, which has a 613 high affinity for both A 1 and A 2A ARs, has been shown to reduce experimental my-614 ocardial ischemia-reperfusion in multiple species when administered both prior to 615 ischemia or during reperfusion (Merkel et al. 1998; McVey et al. 1999; Meng et al. 616 2000; Xu et al. 2001; Kis et al. 2003; Kristo et al. 2004 ). The primary end-point 617 was final myocardial infarct size measured by technetium Tc-99m sestamibi scan-618 ning at 120-216 h after PTCA. Secondary end-points included myocardial salvage 619 and salvage index at the same time interval (in a subset of patients), left ventricular 620 ejection fraction, duration of hospitalization, heart failure at 4-6 weeks, and cardiac 621 events at four weeks and six months. Results indicated that there was no difference 622 in final infarct size or in any of the secondary end-points. There was a trend towards 623 increased myocardial salvage in patients with anterior MI. The authors of this study 624 concluded that, based on the pharmacokinetic data, the maximal dose used in this 625 trial was comparable to the lowest dose proven effective in animal studies.
626
The promising results of AMISTAD I led to a second trial (AMISTAD II) to de-627 termine the effects of adenosine infusion on clinical outcomes and infarct size in 628 ST-segment elevation myocardial infarction (STEMI) patients undergoing reperfu-629 sion therapy (Ross et al. 2005) . A total of 2,118 patients receiving thrombolysis or 630 primary angioplasty were randomized to a 3 h infusion of either adenosine (50 or 631 70 μg kg −1 min −1 ) or placebo. The primary end-point was new congestive heart 632 failure (CHF) beginning >24 h after randomization, or the first rehospitalization for 633 CHF, or death from any cause within six months. Infarct size was measured in a 634 subset of 243 patients by Tc-99m sestamibi tomography. There was no effect of ei-635 ther adenosine dose on primary end-points, although patients receiving the higher 636 dose (70 μg kg −1 min −1 ) exhibited a median infarct size (11%) that was signifi-637 cantly lower (p = 0.023) than that of the placebo group (median infarct size 23%). 638 It was concluded that a larger clinical trial was warranted to determine whether the 639 decreased infarct size observed with adenosine was associated with enhanced long-640 term outcome. A post hoc subanalysis of these data indicated that patients receiving 641 the adenosine infusion within 3 h of the onset of symptoms exhibited significantly 642 reduced mortality at one and six months, and event-free survival was enhanced com-643 pared to patients treated with placebo (Kloner et al 2006) . 644 Given all of the experimental evidence supporting the cardioprotective effects 645 of AR agonists administered either prior to ischemia or during reperfusion, there 646 clearly needs to more research and development into the synthesis, screening, and 647 testing of potent, selective AR agonists. Basic scientists must also utilize consis-648 tent experimental models to determine the specific contributions of the multiple AR 649 subtypes and their mechanisms of action. Because animal efficacy studies do not al-650 ways translate to human efficacy, preclinical models with high relevance to humans 651 and that closely simulate the human condition should be designed. Finally, clinical 652 trials must be better designed along the lines of the information learned from the 653 multitude of preclinical studies and clinical studies performed to date. Ischemic heart disease occurs predominantly in the elderly population (affecting up 656 to 50% of those over 65), and can be associated with multiple underlying disease 657 states, including atherosclerosis, hyperlipidemia, hypertension, and diabetes. From 658 a clinical perspective, it is thus essential that protective strategies derived from re-659 search into PC or other protective modalities are effective across age groups and 660 in diseased hearts. Unfortunately, aging limits or even abrogates protection with 661 PC (Abete et al. 1996; Fenton et al. 2000; Schulman et al. 2001) , AR activation 662 (Gao et al. 2000; Schulman et al. 2001; Headrick et al. 2003; Willems et al. 2005) , AQ2 663 and other GPCR stimuli . Newly discovered postconditioning is 664 also impaired (Przyklenk et al. 2008) . These age-dependent failures may stem from 665 ineffective activation of key components of downstream signaling cascades (Peart 666 et al. 2007; Przyklenk et al. 2008 ). On the other hand, age-related failure of AR-667 dependent protection is not universally observed. For example, Kristo et al. (2005) 668 found no age-related changes in functional AR sensitivity, and augmentation of the 669 infarct-sparing actions of adenosine. Thus, adenosine's role in aged hearts as well 670 as the efficacy of cardioprotection in these hearts by targeting ARs with adenosine 671 or AR agonists are questions that remain open.
672
Disease states underlying or contributing to ischemic disorders (when intrin-673 sic protective responses such as PC are more important) can also impair these 674 responses. For example, Ghosh et al. (2001) showed failure of PC in diabetic hu-675 man myocardium, which may also reflect abnormalities in distal signaling cascades. 676 In terms of AR responses, Donato et al. (2007) showed not only involvement of 677 A 1 ARs (and the mito K ATP channel) in ischemic PC in normal hearts, but con-678 firmed the ability of this stimulus to limit ischemic injury in hypercholesterolemic 679 hearts. Moreover, A 1 and A 3 AR-triggered PC responses appear to be preserved in 680 hypertrophic myocardium (Hochhauser et al. 2007 ). Thus, the few studies to date do 681 support the preservation of AR-mediated protection in animal models of some rele-682 vant disease states. Whether this extends to patients suffering from chronic forms of 683 cardiovascular disease remains to be established. It is worth considering that com-684 bined effects of age and disease may well underlie the rather modest benefit obtained 685 with adenosine in clinical trials (AMISTAD I and II) versus the profound protective 686 responses observed in the laboratory. 
